The initial phase of wound healing (days 0-4 to 6) characterized by hemostasis, immune cell infiltration, debris removal, and establishment of the inflammatory cascade that prepares tissue for repair. This acute inflammatory response must resolve within a precise temporal window to prevent chronification. The phase is marked by sequential neutrophil infiltration (peak 24-48h), followed by M1 macrophage dominance (peak days 2-3), and culminates in M1-to-M2 macrophage polarization (days 4-5) that initiates resolution and repair.
Think of a city after an earthquake. First responders (neutrophils) arrive within hours to search for survivors and clear immediate dangers. They work fast but die quicklyâtheir bodies littering the streets after 48 hours. Within days, a second wave arrives: demolition crews (M1 macrophages) with heavy machinery, tearing down unstable buildings, hauling away debris, and killing any looters (pathogens). These crews generate dust, noise, and traffic jamsânecessary chaos. But if the demolition crews keep working past day 5, the city never rebuilds. The critical transition happens when demolition foremen (M1 macrophages) receive new instructions (via specialized pro-resolving mediators) and switch roles: they become construction managers (M2 macrophages), signaling architects (fibroblasts) and plumbers (angiogenesis) to begin rebuilding. The haematoma is like a temporary dam of sandbagsâit stops the flood (bleeding) but also traps toxic silt (iron from lysed red blood cells) that must be carefully removed before construction begins.
graph TB
A[Tissue Damage] --> B[Platelet Aggregation]
A --> C[DAMP/PAMP Release]
B --> D[Fibrin Clot Formation]
C --> E[Mast Cell Degranulation]
C --> F[Resident Macrophage Activation]
E --> G["Histamine + Heparin Release"]
F --> H["IL-1ÎČ, TNF-α, IL-6 Secretion"]
G --> I["Vasodilation + Permeability"]
H --> I
I --> J[Neutrophil Margination & Extravasation]
J --> K[Neutrophil ROS/RNS Production]
K --> L["Pathogen Killing + Debris Damage"]
L --> M[Neutrophil Apoptosis 48-72h]
M --> N[Monocyte Recruitment]
N --> O[M1 Macrophage Differentiation]
O --> P["M1 Phagocytosis + Pro-inflammatory"]
P --> Q["IL-6, IL-1ÎČ, TNF-α Peak Days 2-3"]
Q --> R[SPM Production EPA/DHA]
R --> S[M2 Macrophage Polarization Days 4-5]
S --> T["TGF-ÎČ, IL-10, VEGF Release"]
T --> U["Resolution + Proliferation Phase"]
Immediate Response (0-4 hours):
Tissue damage â release of DAMPs (HMGB1, ATP, mitochondrial DNA) and PAMPs (if infection present) â activation of resident macrophages and mast cells via TLR4, NLRP3 inflammasome â platelet aggregation via vWF and fibrinogen â fibrin clot formation (hemostasis) â formation of haematoma containing trapped erythrocytes, platelets, and clotting factors.
Neutrophil Phase (4-48 hours):
Activated mast cells release histamine, heparin, and TNF-α â vasodilation and increased vascular permeability â neutrophil margination (rolling via P-selectin, E-selectin) â firm adhesion (ICAM-1, VCAM-1 binding to ÎČ2-integrins) â extravasation via PECAM-1 â chemotaxis toward IL-8, LTB4, C5a gradient. Neutrophils phagocytose debris and pathogens via NADPH oxidase (produces superoxide O2-) and myeloperoxidase (produces hypochlorous acid HOCl). Neutrophil apoptosis begins at 24h, peaks 48-72h â apoptotic neutrophils express "eat me" signals (phosphatidylserine) â efferocytosis by incoming macrophages.
M1 Macrophage Phase (Days 1-4):
Monocytes recruited via MCP-1 (CCL2), MIP-1α â differentiate into M1 macrophages under influence of IFN-Îł, TNF-α, LPS â M1 phenotype characterized by: high iNOS (produces NO), high ROS production, secretion of IL-1ÎČ, IL-6, IL-12, TNF-α â phagocytosis of apoptotic neutrophils, debris, and pathogens â iron sequestration via ferritin (prevents oxidative damage but creates localized hypoxia).
Special Case - Type II Fiber Injury:
Damaged Type II muscle fibers specifically release TNF-α â signals demand for carbohydrate metabolism â glycolytic shift in local metabolism â lactate accumulation if circulation not restored â acidosis risk â HIF-1α stabilization (adaptive initially for angiogenesis signaling, maladaptive if prolonged >4-5 days).
Haematoma-Specific Risks:
Trapped erythrocytes lyse â release free iron (FeÂČâș) â Fenton reaction (FeÂČâș + HâOâ â FeÂłâș + OHâą + OHâ») â hydroxyl radical production â lipid peroxidation â cellular damage â prolonged M1 activation if not cleared.
Resolution Initiation (Days 4-6):
M1 macrophages begin producing 15-LOX enzyme â converts EPA to RvE1, RvE2, RvE3; converts DHA to RvD1-6, MaR1, PD1 â SPMs bind ALX-FPR2, GPR32, GPR18 receptors on M1 macrophages â activate SOCS1/SOCS3 â inhibit NF-ÎșB signaling â downregulate IL-6, TNF-α production â M2 polarization via IL-4, IL-13 (from Th2 cells), IL-10 (autocrine) â M2 macrophages upregulate arginase-1 (competes with iNOS for arginine), CD206 (mannose receptor), TGF-ÎČ, IL-10, VEGF â transition to proliferation phase.
Failed Resolution Mechanisms:
Prolonged M1 â chronic IL-1ÎČ, IL-6 â inhibition of satellite cell differentiation â fibrosis instead of regeneration. Insufficient SPM production (low omega-3 status, COX-2 inhibition by NSAIDs) â persistent inflammation â chronic pain via dorsal horn sensitization.
Clinical Decision-Making Window:
The inflammatory phase represents the most critical intervention timing decision in musculoskeletal rehabilitation. Premature anti-inflammatory intervention (NSAIDs, ice, omega-3 loading in first 72h) impairs neutrophil function, reduces debris clearance, and prevents M1 macrophage activationâleading to incomplete healing, reinjury risk, and chronic pain. Conversely, failure to support timely resolution (days 4-6) locks tissue in chronic inflammation, preventing satellite cell activation and collagen deposition.
Patient Profiles:
- Acute muscle/tendon injuries: Especially Type II fiber dominant injuries (hamstring tears, calf strains, quadriceps contusions) where TNF-α signaling demands carbohydrate availability. Patient must maintain adequate CHO intake days 0-5 to prevent metabolic crisis.
- Post-surgical orthopedic cases: NSAID use perioperatively impairs bone healing by blocking COX-2-dependent PGE2 production, which is essential for osteoblast differentiation.
- Chronic pain patients with acute flare-ups: These patients often have impaired resolution capacity (low omega-3 index <4%, high omega-6:omega-3 ratio >15:1) and may remain stuck in inflammatory phase indefinitely without targeted intervention.
- Athletes with recurrent soft tissue injuries: Often reflect premature return to loading during inflammatory phase (before M2 transition) or chronic low-grade inflammation from previous incomplete resolution.
Metamodel Connections:
This phase exemplifies selfish immune system behaviorâthe inflammatory response prioritizes pathogen defense and damage containment over tissue function. The immune system recruits metabolic resources (glucose, amino acids) away from muscle protein synthesis toward immune cell function. Simultaneously demonstrates evolutionary mismatch: modern anti-inflammatory interventions (NSAIDs, cryotherapy protocols) disrupt an evolutionarily conserved healing sequence optimized for infection control in resource-scarce environments, not sterile athletic injuries in resource-abundant settings.
Biomarkers and Thresholds:
- IL-6: Should peak days 2-3 (>10 pg/mL locally), then decline by day 5. Persistently elevated IL-6 (>5 pg/mL systemically beyond day 7) indicates failed resolution.
- CRP: Acute phase response peaks 24-72h (can reach >100 mg/L in severe trauma), should halve every 48h thereafter. CRP >10 mg/L beyond day 14 indicates chronification.
- Neutrophil-lymphocyte ratio: Should peak day 1-2 (>5:1), normalize by day 5-7. Persistent elevation suggests ongoing acute inflammation.
- Procalcitonin: Should remain low (<0.5 ng/mL) unless bacterial infection present. Elevation indicates need for antimicrobial intervention, not just inflammation management.
Intervention Strategy:
Days 0-3: Support acute inflammationâensure adequate protein (1.6-2.2 g/kg), carbohydrate (especially if Type II fibers injured, 4-6 g/kg), vitamin C (1000-2000mg), zinc (30-45mg), vitamin A (3000-5000 IU). Avoid NSAIDs unless pain catastrophizing threatens sleep/stress axes. Gentle movement to prevent DVT and maintain nutrient delivery, but avoid mechanical loading that re-injures tissue.
Days 3-5: Initiate resolution supportâintroduce EPA/DHA (2-4g combined), specialized pro-resolving mediator precursors. Begin gradual reloading to provide mechanical signals for collagen alignment. Monitor pain responseâincreasing pain indicates premature loading.
Days 5-7: Confirm M2 transitionâpain should be declining, ROM improving. Increase loading progressively. If pain plateau or increase, suspect failed resolutionâincrease omega-3, consider curcumin (inhibits NF-ÎșB), resveratrol (activates SIRT1), or other resolution agonists.
Contraindicated Interventions:
- NSAIDs days 0-14 for bone/muscle/tendon healing (COX-2 required for tissue repair)
- Corticosteroids (block phospholipase A2, prevent SPM synthesis)
- High-dose omega-3 days 0-3 (may blunt necessary acute inflammation)
- Aggressive cryotherapy beyond 48h (impairs M1 macrophage function)
- Complete immobilization >72h (causes muscle atrophy, impairs circulation)
- Duration highly conserved across tissue types: 0-4 to 6 days for uncomplicated wounds, prolonged in diabetics (10-14 days), elderly (7-10 days), or immunocompromised
- Neutrophils dominate first 24-48 hours with peak influx at 24h, then undergo apoptosis with >90% cleared by 72hâapoptotic neutrophils are "eat me" signals for macrophage recruitment
- M1 macrophages peak days 2-3, must phenotypically switch to M2 by days 4-5 for normal healingâfailure of M1âM2 transition is the most common cause of chronic wound inflammation
- Haematoma provides growth factors (PDGF, TGF-ÎČ, VEGF from platelets) but also oxidative threatâfree iron from lysed RBCs generates hydroxyl radicals via Fenton chemistry requiring rapid clearance
- Type II muscle fibers specifically produce TNF-α during inflammatory phase signaling carbohydrate demandâinadequate CHO availability during this phase impairs healing and increases fibrosis risk
- HIF-1α activation is biphasic: protective days 0-3 (drives VEGF for angiogenesis), damaging if sustained beyond day 5 (promotes fibrosis, inhibits oxidative metabolism)
- COX-2 upregulation during inflammatory phase is essentialâproduces PGE2 which stimulates osteoblast differentiation (bone), satellite cell activation (muscle), and fibroblast proliferation (tendon/ligament)
- Omega-3 supplementation timing is critical: avoid loading doses days 0-3 (may impair acute inflammation), introduce days 3-5 (supports resolution), continue through day 21 (prevents chronic inflammation)
- IL-6 has context-dependent dual roles: pro-inflammatory when released by M1 macrophages with TNF-α (days 1-3), anti-inflammatory/myokine when released by contracting muscle or M2 macrophages (days 5+)
- Specialized pro-resolving mediators (SPMs) are actively synthesized starting day 3-4, not passively producedârequire EPA/DHA substrate, functional 15-LOX enzyme, and permissive redox environment
- Failed resolution biomarker: IL-6 >5 pg/mL systemically beyond day 7, CRP >10 mg/L beyond day 14, persistent neutrophil-lymphocyte ratio >3:1 beyond day 7
- Satellite cell activation begins during late inflammatory phase (days 4-6) but differentiation blocked if M1 cytokines persistâexplains why NSAIDs impair muscle mass recovery even weeks post-injury
- wound healing â is the foundational first phase of the three-phase healing cascade
- proliferation phase â must successfully transition to by day 4-6 via M2 macrophage polarization
- maturation phase â precedes the final remodeling phase that can last 8 days to 2 years
- M1 macrophages â dominated by this pro-inflammatory phenotype days 2-4 with peak IL-6, TNF-α, IL-12 production
- M2 macrophages â critical transition to this anti-inflammatory/pro-resolution phenotype by days 4-5 determines healing success
- neutrophils â first responder cells arriving within hours, peak 24h, undergo apoptosis 48-72h
- TNF-α â key pro-inflammatory cytokine produced by activated macrophages and Type II muscle fibers during injury
- IL-1ÎČ â NLRP3 inflammasome-dependent cytokine driving acute phase response and fever during this phase
- IL-6 â context-dependent cytokine: pro-inflammatory when co-released with TNF-α during early phase, myogenic when released alone later
- haematoma â fibrin clot structure containing platelets, growth factors, and oxidative threat from iron
- satellite cells â muscle stem cells that begin activation days 4-6 but require M2 environment for differentiation
- Type II fibers â fast-twitch glycolytic fibers that produce TNF-α when damaged, signaling carbohydrate metabolic demand
- HIF â hypoxia-inducible factor stabilized during inflammatory phase, essential early but pathological if sustained
- resolvomics â the active biochemical process of inflammation resolution initiated days 3-5 via SPM production
- specialized pro-resolving mediators â lipid mediators (resolvins, maresins, protectins) synthesized from EPA/DHA starting day 3-4 that drive M1âM2 transition
- omega-3 fatty acids â timing critical: avoid high doses days 0-3, introduce days 3-5 to provide SPM substrate
- NSAIDs â block COX-2 required for PGE2 production, impairing bone healing, satellite cell activation, and SPM synthesis
- angiogenesis â new blood vessel formation initiated during late inflammatory phase via VEGF from M2 macrophages
- collagen synthesis â begins during proliferation phase but groundwork laid in late inflammatory phase via TGF-ÎČ signaling
- COX-2 â cyclooxygenase-2 enzyme upregulated during inflammation, produces PGE2 essential for tissue repair despite pro-inflammatory reputation
- efferocytosis â M1 macrophage clearance of apoptotic neutrophils beginning day 2, triggers resolution program
- DAMPs â damage-associated molecular patterns (HMGB1, ATP, mtDNA) released by necrotic cells that activate NLRP3 and TLR4 to initiate inflammation
- NLRP3 inflammasome â multiprotein complex activated by DAMPs during tissue damage, processes pro-IL-1ÎČ to active IL-1ÎČ
- mast cells â resident immune cells that degranulate immediately upon injury, releasing histamine, heparin, TNF-α to initiate vascular response
- ROS â reactive oxygen species produced by neutrophils (via NADPH oxidase) and M1 macrophages for pathogen killing but also cause bystander tissue damage
- TGF-ÎČ â transforming growth factor-beta released by M2 macrophages and platelets, drives fibroblast activation and collagen deposition
- VEGF â vascular endothelial growth factor produced downstream of HIF-1α and by M2 macrophages, initiates angiogenesis
- acute inflammation â the broader category of rapid-onset immune responses of which this healing phase is the prototypical example
- chronic inflammation â pathological state resulting from failed resolution when inflammatory phase extends beyond 7-14 days
- Module 5 â Connective Tissue and Wound Healing
- Module 6 â Musculoskeletal System and Tissue Repair